Pantostad 20

Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production.

Pack size Box of 14 tablets, 28 tablets, 30 tablets, 50 tablets
Shelf-life 36 months
Composition Pantoprazole
Dosage forms and strengths Enteric-coated tablet 20 mg
Product code :



  • Gastro-oesophageal reflux disease (GERD).
  • Peptic ulcer disease.
  • Prophylaxis for NSAID-associated ulceration.
  • Zollinger-Ellison syndrome.


  • Gastro-oesophageal reflux disease (GERD)
    + The usual dose: 20 to 40 mg once daily for 4 weeks, increased to 8 weeks if necessary.
    + Maintenance therapy: Treatment can be continued with 20 to 40 mg daily. For recurring symptoms, an on-demand of 20 mg daily may be given.
  • Peptic ulcer disease
    The usual dose is 40 mg once daily. Treatment is given for 2 to 4 weeks for duodenal ulceration, or 4 to 8 weeks for benign gastric ulceration. For the eradication of Helicobacter pylori, pantoprazole may be combined with two antibacterials in a 1-week triple therapy regimen. Effective regimens include pantoprazole 40 mg twice daily combined with clarithromycin 500 mg twice daily and either amoxicillin 1 g twice daily or metronidazole 400 mg twice daily.
  • Prophylaxis for NSAID – associated ulceration
    The dose is 20 mg daily.
  • Treatment of pathological hypersecretory states (Zollinger-Ellison syndrome)
    The initial dose is 80 mg daily, adjusted as required. Doses of up to 240 mg daily have been used. Daily doses greater than 80 mg should be given in 2 divided doses.
  • Administration in hepatic impairment
    Dosage of pantoprazole may needed to be reduced in severe hepatic impairment, or doses given only on alternate days. A maximum dose of 20 mg daily, or 40 mg on alternate days, has been suggested.
  • Administration in renal impairment
    A maximum dose of 40 mg daily should be observed.

Pantostad 20 is administered orally. Once-daily doses should be taken in the morning.

Known hypersensitivity to pantoprazole, to any other ingredient in the formulation, or other substituted benzimidazoles (e.g., esomeprazole, lansoprazole, omeprazole, rabeprazole).

  • Pantoprazole may increase the risk of gastrointestinal infections.
  • The common adverse reactions were fatigue, headache; rash, urticaria, myalgia, arthralgia.
  • Symptomatic response to therapy with pantoprazole does not preclude the presence of gastric neoplasm and pantoprazole may alleviate the symptoms and delay diagnosis.
  • Mild, transient elevations of serum ALT (SGPT).
  • Hypochlorhydria or achlorhydria may lead to malabsorption of cyanocobalamin.
  • Safety and efficacy in children younger than 18 years of age have not been established.
  • Patients with rare hereditary problems of fructose intolerance should not take Pantostad 20.
  • Pantostad 20 is to say essentially “sodium-free”.
  • There are no adequate and well-controlled studies in pregnant women.
  • Pantoprazole is distributed into milk; discontinue nursing or the drug.
  • There are no known effects of the drug on the ability to drive or operate machinery.